gsk3359609
mAbexperimental
Clinical trial activity
10 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
8
Phase 3
2
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02723955)
Timeline
Indications
Mechanism of action
Inducible T-cell costimulator agonist
- Inducible T-cell costimulatorINHIBITOR
ICOS inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297969 ↗
Also known as
- gsk3359609
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04428333 | Phase 3 | Jul 15, 2020 | GlaxoSmithKline, Merck |
| NCT07217119 | Phase 1/Phase 2 (Phase 2) | Nov 26, 2019 | GlaxoSmithKline |
| NCT04128696 | Phase 3 | Nov 18, 2019 | GlaxoSmithKline, Merck |
| NCT04126200 | Phase 2 | Oct 7, 2019 | GlaxoSmithKline |
| NCT05553808 | Phase 2 | Jan 24, 2019 | GlaxoSmithKline, iTeos Therapeutics |
| NCT06790303 | Phase 2 | Jan 24, 2019 | GlaxoSmithKline |
| NCT03739710 | Phase 2 | Jan 24, 2019 | GlaxoSmithKline |
| NCT03693612 | Phase 2 | Nov 26, 2018 | GlaxoSmithKline, MedImmune |
| NCT03447314 | Phase 1 | Mar 26, 2018 | GlaxoSmithKline, IQVIA |
| NCT02723955 | Phase 1 | Jun 1, 2016 | GlaxoSmithKline, Merck |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 10 | 10 | 3 | 2016 |
| Merck | For profit | 3 | 0 | 2 | 2016 |
| IQVIA | For profit | 1 | 0 | 1 | 2018 |
| iTeos Therapeutics | For profit | 1 | 0 | 1 | 2019 |
| MedImmune | For profit | 1 | 0 | 1 | 2018 |
5 organizations
Page 1 / 1